Elsevier

Journal of Hepatology

Volume 64, Issue 4, April 2016, Pages 933-945
Journal of Hepatology

Review
Pregnancy and liver disease

https://doi.org/10.1016/j.jhep.2015.11.030Get rights and content

Section snippets

Summary

Pregnancy associated liver diseases affect up to 3% of pregnant women and are the most frequent cause of liver dysfunction in pregnancy. When severe, they are associated with significant morbidity and mortality for both mother and infant [1], [2], [3]. A rapid evaluation to distinguish them from non-pregnancy related liver dysfunction is essential, in order to facilitate appropriate management. Liver disease unrelated to pregnancy can present de novo in pregnancy, or pregnancy can occur in

Normal physiological changes in pregnancy

In a normal pregnancy many physiological and hormonal changes occur within the human body, some of which can mimic those seen in women with liver disease. There is a rise in maternal heart rate, cardiac output increases by 40%, the circulating plasma volume increases by 30% and there is a reduction in peripheral vascular resistance. These physiological changes result in a hyper-dynamic circulation; a physiological state that is common in patients with decompensated chronic liver disease.

Pregnancy related liver diseases

The liver diseases specific to the pregnant state can be classified into those of early pregnancy (hyperemesis gravidarum (HG)) and those of late pregnancy (acute fatty liver of pregnancy (AFLP), pre-eclampsia with hepatic involvement including haemolysis, elevated liver enzymes and low platelets (HELLP) syndrome, liver rupture/infarction and intrahepatic cholestasis of pregnancy (ICP)). The typical pattern of abnormal serum liver tests in specific gestational liver diseases are given in Table 3

Hyperemesis gravidarum

HG is the most severe form of illness within the spectrum of nausea and vomiting of pregnancy. It is defined as intractable vomiting, resulting in dehydration, ketosis and weight loss of greater than 5%. It complicates between 0.3% and 2% of pregnancies and symptoms usually but not exclusively begin before 9 weeks gestation [6], [7]. The exact aetiology of HG is unclear. Human chorionic gonadotropin (HCG) hormone, which peaks in the first trimester has been shown to correlate with the severity

Intrahepatic cholestasis of pregnancy

Intrahepatic cholestasis of pregnancy (ICP) is the commonest pregnancy-specific liver disease. It is a reversible form of cholestasis characterized by pruritus in pregnancy and elevated fasting or post-prandial serum bile acids with spontaneous relief of signs and symptoms within 6 weeks of delivery [20]. ICP has a high recurrence rate in subsequent pregnancies. It has a variable incidence, ranging from 3–5% of pregnant women in Chile, to 0.7% in the UK; it is rarely reported in African

Pre-eclampsia, eclampsia and haemolysis, elevated liver enzymes, low platelets (HELLP) syndrome

Pre-eclampsia is a multisystem disorder defined by the international society for the study of hypertension in pregnancy as de novo hypertension after the 20th week of pregnancy (blood pressure (BP) 140/90) combined with proteinuria (>300 mg/day), other maternal organ dysfunction, such as renal insufficiency, liver involvement, neurological or haematological complications, uteroplacental dysfunction, or fetal growth restriction [47]. In a patient with pre-existing essential hypertension,

Hepatic rupture, infarction and haematoma

Hepatic haemorrhage and rupture can complicate pre-eclampsia, eclampsia, HELLP syndrome and patients with AFLP and is associated with a 50% mortality [63]. Patients can present with abdominal pain, pyrexia and, if severe, hypovolaemic shock and cardiovascular collapse. Laboratory investigations reveal transaminases in the several thousands, leucocytosis and anaemia. Imaging in the form of computed tomography or magnetic resonance is the investigation of choice [64]. Contained haematomas can be

Acute fatty liver of pregnancy

AFLP is a medical and obstetric emergency as it can be fatal for both the mother and baby without early recognition and appropriate management [69], [70]. It is a rare complication of pregnancy, usually occurring in the third trimester, and in the UK affects approximately 1 in 20,000 pregnancies [71], with the true incidence likely however to be higher with underreporting of subclinical/milder forms. Risk factors include nulliparity, male infants and twin pregnancies.

The presentation is similar

Cirrhosis and portal hypertension

In women with cirrhosis, fertility is reduced and pregnancy is rare secondary to metabolic and endocrine dysfunction [1], [81], [82], [83], [84], [85], [86]. Disruption of the hypothalamic-pituitary axis in conjunction with disturbed oestrogen metabolism leads to anovulation, amenorrhoea and infertility [84], [85]. When pregnancy does occur there is an increased rate of spontaneous pregnancy loss, preterm labour and perinatal death [87]. For the mother there is a risk of worsening liver

Acute viral infections and pregnancy

Acute viral hepatitis is the commonest cause of jaundice occurring in pregnancy worldwide [150]. Hepatitis A virus infection in pregnancy has a clinical course similar to the non-pregnant population and fulminant hepatitis is rare [151]. Although hepatitis A virus infection in pregnancy is not a major cause of maternal or neonatal morbidity, in utero infection has been associated with fetal meconium peritonitis, neonatal cholestasis and preterm labour [152], [153], [154]. It is therefore

Conclusion

Liver disease in pregnancy and pregnancy in women with liver disease is rare. However, this is a clinically important group of patients due to the increased morbidity and mortality for both the mother and baby. The spectrum of disease and presentation varies hugely, resulting in delays in diagnosis and appropriate management. The disorders are complex and patients benefit from multi-disciplinary input by experienced physicians in specialist centres. It is important to ensure that women of

Conflict of interest

The authors who have taken part in this study declared that they do not have anything to disclose regarding funding or conflict of interest with respect to this manuscript.

First page preview

First page preview
Click to open first page preview

References (194)

  • V. Geenes et al.

    Rifampicin in the treatment of severe intrahepatic cholestasis of pregnancy

    Eur J Obstet Gynecol Reprod Biol

    (2015)
  • J. Kondrackiene et al.

    Efficacy and safety of ursodeoxycholic acid versus cholestyramine in intrahepatic cholestasis of pregnancy

    Gastroenterology

    (2005)
  • E.A. Wikstrom Shemer et al.

    Intrahepatic cholestasis of pregnancy and cancer, immune-mediated and cardiovascular diseases: a population-based cohort study

    J Hepatol

    (2015)
  • A.L. Tranquilli et al.

    The classification, diagnosis and management of the hypertensive disorders of pregnancy: a revised statement from the ISSHP

    Pregnancy Hypertens

    (2014)
  • A. Green et al.

    OS102. Continuing pathology following a hypertensive pregnancy and the risk of future disease

    Pregnancy Hypertens

    (2012)
  • E. Seely et al.

    Preeclampsia and future cardiovascular disease in women: how good are the data and how can we manage our patients?

    Semin Perinatol

    (2015)
  • L. Weinstein

    Syndrome of hemolysis, elevated liver enzymes, and low platelet count: a severe consequence of hypertension in pregnancy. 1982

    Am J Obstet Gynecol

    (2005)
  • J.N. Martin et al.

    Understanding and managing HELLP syndrome: the integral role of aggressive glucocorticoids for mother and child

    Am J Obstet Gynecol

    (2006)
  • B.M. Sibai et al.

    Maternal morbidity and mortality in 442 pregnancies with hemolysis, elevated liver enzymes, and low platelets (HELLP syndrome)

    Am J Obstet Gynecol

    (1993)
  • B. Haddad et al.

    Risk factors for adverse maternal outcomes among women with HELLP (hemolysis, elevated liver enzymes, and low platelet count) syndrome

    Am J Obstet Gynecol

    (2000)
  • D. Greenstein et al.

    Liver hemorrhage: recurrent episodes during pregnancy complicated by preeclampsia

    Gastroenterology

    (1994)
  • M.F. Fesenmeier et al.

    Acute fatty liver of pregnancy in 3 tertiary care centers

    Am J Obstet Gynecol

    (2005)
  • M.A. Castro et al.

    Reversible peripartum liver failure: a new perspective on the diagnosis, treatment, and cause of acute fatty liver of pregnancy, based on 28 consecutive cases

    Am J Obstet Gynecol

    (1999)
  • R.H. Westbrook et al.

    Model for end-stage liver disease score predicts outcome in cirrhotic patients during pregnancy

    Clin Gastroenterol Hepatol

    (2011)
  • M.J. Whelton et al.

    Pregnancy in patients with hepatic cirrhosis. Management and outcome

    Lancet

    (1968)
  • B.S. Sandhu et al.

    Pregnancy and liver disease

    Gastroenterol Clin North Am

    (2003)
  • N. Aggarwal et al.

    Non-cirrhotic portal hypertension in pregnancy

    Int J Gynaecol Obstet

    (2001)
  • G.G. Zeeman et al.

    Prophylactic banding of severe esophageal varices associated with liver cirrhosis in pregnancy

    Obstet Gynecol

    (1999)
  • S. O’Mahony

    Endoscopy in pregnancy

    Best Pract Res Clin Gastroenterol

    (2007)
  • R. de Franchis

    Expanding consensus in portal hypertension: report of the Baveno VI Consensus Workshop: stratifying risk and individualizing care for portal hypertension

    J Hepatol

    (2015)
  • P. Starkel et al.

    Endoscopic band ligation: a safe technique to control bleeding esophageal varices in pregnancy

    Gastrointest Endosc

    (1998)
  • N. Aggarwal et al.

    Pregnancy with portal hypertension

    J Clin Exp Hepatol

    (2014)
  • F. Henry et al.

    Blood vessel changes during pregnancy: a review

    Am J Clin Dermatol

    (2006)
  • D.B. Rolfes et al.

    Liver disease in pregnancy

    Histopathology

    (1986)
  • D.V. Fairweather

    Nausea and vomiting during pregnancy

    Obstet Gynecol Annu

    (1978)
  • D.B. Fell et al.

    Risk factors for hyperemesis gravidarum requiring hospital admission during pregnancy

    Obstet Gynecol

    (2006)
  • C.M. Lockwood et al.

    Serum human chorionic gonadotropin concentrations greater than 400,000 IU/L are invariably associated with suppressed serum thyrotropin concentrations

    Thyroid

    (2009)
  • B.K. Gill et al.

    A study of thyroid status in hyperemesis gravidarum

    Indian J Clin Biochem

    (2007)
  • N.K. Kuscu et al.

    Hyperemesis gravidarum: current concepts and management

    Postgrad Med J

    (2002)
  • Practice Bulletin Summary No153: nausea and vomiting of pregnancy

    Obstet Gynecol

    (2015)
  • I. Matok et al.

    The safety of metoclopramide use in the first trimester of pregnancy

    N Engl J Med

    (2009)
  • A. Matthews et al.

    Interventions for nausea and vomiting in early pregnancy

    Cochrane Database Syst Rev

    (2015)
  • A. Einarson et al.

    The safety of ondansetron for nausea and vomiting of pregnancy: a prospective comparative study

    BJOG

    (2004)
  • L. Park-Wyllie et al.

    Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta-analysis of epidemiological studies

    Teratology

    (2000)
  • J.M. Conchillo et al.

    Liver enzyme elevation induced by hyperemesis gravidarum: aetiology, diagnosis and treatment

    Neth J Med

    (2002)
  • EASL Clinical Practice Guidelines: management of cholestatic liver diseases

    J Hepatol

    (2009)
  • V. Geenes et al.

    Intrahepatic cholestasis of pregnancy

    World J Gastroenterol

    (2009)
  • X. Song et al.

    Transcriptional dynamics of bile salt export pump during pregnancy: mechanisms and implications in intrahepatic cholestasis of pregnancy

    Hepatology

    (2014)
  • S. Abu-Hayyeh et al.

    Prognostic and mechanistic potential of progesterone sulfates in intrahepatic cholestasis of pregnancy and pruritus gravidarum

    Hepatology

    (2015)
  • ...
  • Cited by (0)

    View full text